PHARMACY

J&J subsidiary seeks approval for Type 2 diabetes drug

BY Alaric DeArment

RARITAN, N.J. — A subsidiary of Johnson & Johnson is seeking regulatory approval for a new Type 2 diabetes drug.

J&J division Janssen Research & Development announced Wednesday that it had filed with the Food and Drug Administration for a drug combining the experimental drug canagliflozin and immediate-release metformin, a common generic drug for diabetes.

The company also submitted a regulatory approval application to the FDA for canagliflozin in May 2012.


Interested in this topic? Sign up for our weekly DSN Collaborative Care e-newsletter. 

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

PHARMACY

ViroPharma launches hereditary angioedema campaign

BY Alaric DeArment

EXTON, Pa. — Drug maker ViroPharma has launched an education campaign focused on a rare, debilitating and life-threatening genetic disorder.

The company announced Wednesday the launch of the unbranded campaign focused on hereditary angioedema, particularly the emotional and psychological burden faced by patients with the disease, which results from deficiency of the human plasma protein C1 inhibitor and causes attacks of swelling and pain.

The company said HAE patients can experience multiple attacks per month, but attacks are highly variable and unpredictable, causing patients to experience anxiety, depression and isolation.

"Through this campaign, we hope to illustrate that HAE is not just an acute clinical condition, but can also be an emotional and psychological burden to patients," ViroPharma associate director of marketing Frank Nazzario said. "HAE is a life-altering disease that interferes with work, school, travel and social life."


Interested in this topic? Sign up for our weekly DSN Collaborative Care e-newsletter.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

PHARMACY

Galderma Pharma to acquire Spirig Pharma

BY Alaric DeArment

LAUSANNE, Switzerland — Swiss skin drug maker Galderma Pharma will acquire another Swiss drug maker also focused on treatments for skin conditions, Galderma said.

Based in Egerkingen, Switzerland, Spirig makes treatments for such conditions as solar damage and skin barrier function impairment, as well as treatments for such precancerous conditions as actinic keratosis. Financial terms of the deal were not disclosed, though it was noted that Spirig had sales of about $106 million in 2011. The global corporate headquarters of Galderma will remain in Lausanne, Switzerland.

"We are excited about our two companies’ commercial and geographic opportunities, maximizing the value of our complementary product portfolios in the prescription and self-medication markets," Galderma VP business development and markets Albert Draaijer said. "We look forward to welcoming Spirig employees and to combining our efforts to better meet the market’s needs."


Interested in this topic? Sign up for our weekly DSN Collaborative Care e-newsletter. 

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES